Analyst Ratings for Brainstorm Cell Therapeutics (BCLI)

BCLI Rating Summary

  |   Expand Research on BCLI
Overall Rating: BUY   Rating Trend: Up   Avg. $ Target: N/A
Rating Score: 6.7 / 10   Percentile Rank: 71%
Date Firm Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
7/23/2025 Maxim Group Jason McCarthy Downgrade Hold
(Buy)		 N/A
(N/A)		 1.17
(1.17)		 0% Details
12/18/2018 Dawson James
» Updated 5/25/2022		 Jason Kolbert New Coverage Buy
(N/A)		 N/A
(N/A)		 3.05
(1.17)		 -61.64% Details